We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCorvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
11.3696 USD -0.10 ( 0.88%)
Last update at 2026-11-12T15:47:00Z
VOLUME
107998
Market Cap
1089.37M

Momentum Score

…

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.89
Low
11.37
High
52 Week Price Range
5.74
Low
26.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies that modulate the tumor microenvironment. Long-term growth may be driven by clinical data readouts, regulatory milestones, strategic partnerships and pipeline advancement, and the company could benefit if its programs demonstrate safe, effective activity.
Material risks include high clinical and regulatory risk with potential trial failure, limited or no product revenues requiring external financing that may dilute shareholders, and significant competition from larger oncology developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.47
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-35.43%
Net Debt
-3.64M
ROCE
-69.77%
Diluted EPS TTM
-0.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -15.28M -62.29M -27.03M -41.31M -43.24M
Net income -15.28M -62.29M -27.03M -50.05M -38.20M
Selling general administrative 9.25M 8.16M 6.88M 8.10M 9.52M
Selling and marketing expenses - - 0.15M - -
Gross profit -0.10M -0.09M -0.15M - -
Reconciled depreciation 0.10M 0.09M 0.22M 0.37M 0.46M
Ebit -43.08M -27.55M -23.41M -32.56M -38.63M
Ebitda -42.97M -27.46M -23.26M -32.59M -43.23M
Depreciation and amortization 0.10M 0.09M 0.15M -0.02M -4.60M
Operating income -42.97M -27.55M -23.41M -32.56M -38.63M
Other operating expenses 42.97M 27.55M 23.41M 32.56M 38.63M
Interest expense 2.50M 1.82M 1.58M 0.65M 0.01M
Interest income 2.50M 1.82M 1.58M - -
Net interest income 2.50M 1.82M 1.52M 0.65M -0.01M
Income tax expense - - - 8.74M -5.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 42.87M 27.55M 23.41M 32.56M 38.63M
Cost of revenue 0.10M 0.09M 0.15M - -
Total other income expense net 27.69M -34.74M -3.62M -8.74M -4.61M
Net income from continuing ops -15.28M -62.29M -30.19M -41.31M -43.24M
Net income applicable to common shares - - - -41.31M -43.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 71.12M 68.91M 45.55M 68.24M 109.45M
Other current assets 1.09M 2.23M 0.74M 0.10M 0.13M
Total liab 9.91M 36.34M 6.87M 12.12M 12.29M
Total stockholder equity 61.20M 32.57M 38.68M 56.12M 97.16M
Other current liab 6.49M 32.63M 3.97M 7.55M 0.12M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -412.29M -397.01M -334.72M -307.69M -266.38M
Other assets - - 0.00M 0.13M 0.24M
Cash 4.58M 8.74M 12.62M 13.16M 63.46M
Total current liabilities 9.38M 35.40M 6.87M 12.12M 12.29M
Current deferred revenue - - - - 6.96M
Net debt -3.64M -7.62M -11.25M -10.56M -59.81M
Short term debt 0.40M 0.18M 1.37M 2.60M 3.65M
Short long term debt total 0.94M 1.12M 1.37M 2.60M 3.65M
Other stockholder equity 474.39M 430.86M 374.36M 364.36M 361.67M
Property plant equipment - - - - 3.64M
Total current assets 58.21M 54.41M 27.96M 42.30M 69.45M
Long term investments 10.99M 12.54M 16.12M 21.88M 34.27M
Net tangible assets - - - 56.12M 97.16M
Short term investments 52.17M 43.22M 14.53M 29.14M 5.99M
Net receivables 0.37M 0.22M 0.06M 0.63M 0.54M
Inventory - - - -0.73M -0.67M
Accounts payable 2.49M 2.58M 1.52M 1.98M 1.56M
Accumulated other comprehensive income -0.90M -1.29M -0.97M -0.56M 1.87M
Non currrent assets other 0.85M 0.63M 0.09M 1.84M 2.55M
Non current assets total 12.90M 14.50M 17.60M 25.94M 40.00M
Capital lease obligations 0.94M 1.12M 1.37M 2.60M 3.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -7.62M -27.48M 13.98M -23.28M 21.57M
Change to liabilities - - - 0.41M -1.90M
Total cashflows from investing activities -7.80M -27.48M 15.54M -23.28M 21.56M
Total cash from financing activities 36.43M 49.03M 7.86M 0.00M 62.16M
Change to operating activities - - - 1.08M -0.83M
Net income -15.28M -62.29M -27.03M -41.31M -43.24M
Change in cash -4.16M -3.88M -0.54M -50.30M 47.00M
Begin period cash flow 8.74M 12.62M 13.16M 63.46M 16.45M
End period cash flow 4.58M 8.74M 12.62M 13.16M 63.46M
Total cash from operating activities -32.80M -25.42M -23.93M -27.02M -36.72M
Issuance of capital stock 0.00M 16.41M 7.84M 0.00M 60.94M
Depreciation 0.10M 0.09M 0.15M 0.37M 0.46M
Other cashflows from investing activities - 0.01M - - -
Change to account receivables 0.04M -0.05M 0.56M -0.08M -0.51M
Other cashflows from financing activities 36.43M 32.62M 0.01M -23.28M 1.22M
Change to netincome - - - - 9.30M
Capital expenditures 0.17M 0.00M 0.03M 0.27M 0.01M
Change in working capital 3.58M -1.65M -3.59M 1.41M -3.24M
Stock based compensation 5.33M 3.00M 2.15M 2.69M 4.23M
Other non cash items -26.53M 35.43M 4.39M 9.81M 5.07M
Free cash flow -32.97M -25.42M -23.97M -27.29M -36.72M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CRVS
Corvus Pharmaceuticals Inc		 -0.10
0.88%		 11.37 - - - 4.89 0.36
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

901 Gateway Boulevard, South San Francisco, CA, United States, 94080

650 900 4520

https://www.corvuspharma.com

37

Name Title Year Born
Dr. Richard A. Miller M.D. Co-Founder, Pres, CEO & Chairman 1951
Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Director 1960
Mr. Leiv Lea Chief Financial Officer 1954
Dr. William Benton Jones Ph.D. Sr. VP of Pharmaceutical Devel. 1966
Dr. Erik J. Verner Ph.D. Co-Founder 1965
Dr. James T. Rosenbaum M.D. Sr. VP of Research NA
Mr. Alan C. Mendelson Esq. Sec. NA
Dr. Richard A. Miller M.D. Co-Founder, President, CEO & Chairman of the Board 1951
Dr. William Benton Jones Ph.D. Senior Vice President of Pharmaceutical Development 1966
Dr. James T. Rosenbaum M.D. Senior Vice President of Research NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…